Low
₹
High
₹
| Previous Close | ₹97.50 |
|---|---|
| Day's Range | ₹90.00 - ₹98.69 |
| Open | ₹98.69 |
| 52 Week Range | ₹73.04 - ₹189.00 |
| Volume | 107 |
| Market Cap | ₹0.00 |
| Trade Value ( ₹ in Lacs) | 0.10 |
|---|---|
| Market Cap (₹ in Mn) | 0.00 |
| Dividend Yield(%) | 0.00 |
| Price/Earning (TTM) | 0.00 |
| TTM EPS (₹) | -3.96 |
| P/E Ratio | 0.00 |
| Book Value(₹) | 1.29 |
| PAT Margin (%) | -2.73 |
| Face Value (₹) | 10.00 |
| ROCE(%) | 5.09 |
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 129.36 | 535.16 |
| Expenses | N/A | N/A |
| PBT | -0.39 | -16.18 |
| Operating profit | 0.0 | 0.0 |
| Net profit | -0.39 | -14.64 |
| Founded | 1995 |
|---|---|
| Managing Director | Vijay Majrekar |
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,56,089.58 | 1,900.90 | 1,548.00 - 1,548.00 |
| Divi's Laboratories Ltd. | 2,26,975.64 | 8,550.00 | 5,636.50 - 5,636.50 |
| Torrent Pharmaceuticals Ltd. | 1,85,638.53 | 4,880.50 | 3,480.60 - 3,480.60 |
| Apollo Hospitals Enterprise Ltd. | 1,24,503.13 | 8,659.00 | 6,696.50 - 6,696.50 |
| Cipla Ltd. | 1,15,216.02 | 1,426.20 | 1,165.70 - 1,165.70 |
| Lenskart Solutions Ltd. | 1,15,063.80 | 661.55 | 0.00 - 0.00 |
| Zydus Lifesciences Ltd. | 1,11,720.43 | 1,120.00 | 835.50 - 835.50 |
| Lupin Ltd. | 1,00,271.61 | 2,193.00 | 1,875.00 - 1,875.00 |
| Dr. Reddy's Laboratories Ltd. | 98,074.41 | 1,175.00 | 1,101.00 - 1,101.00 |
| Laurus Labs Ltd. | 98,047.76 | 1,814.65 | 823.10 - 823.10 |
No Records Found
In Compliances with Regulation 47 of the SEBI (LODR) Regulations, 2015, Centenial Surgical Suture has informed that it enclosed copies of the Newspaper Advertisement of the Standalone Audited Financial Results of the Company for the quarter and year ended March 31, 2026 published in all the editions of New Hub and in Mumbai Edition of Pratahkal (Regional Newspaper) on June 2, 2026.
The above information is a part of company’s filings submitted to BSE.
Pursuant to Regulation 30(6) read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015, as amended from time to time, Concord Biotech has informed that the officials of the Company will be attending an Investor Conference on 26th August 2026 at 01:00 PM to 03:00 PM (IST) organised by Phillip Capital PCG in Ahmedabad. Discussions will be based on publicly available information. No unpublished price sensitive information (UPSI) is intended to be discussed during the interactions.
The above information is a part of company’s filings submitted to BSE.
Glenmark Pharmaceuticals has informed that, Glenmark Pharmaceuticals Inc., USA (Glenmark) today announced the launch1 of Calcium Gluconate Injection USP, 1,000 mg/10 mL (100 mg/mL) Single-Dose Vials, 5,000 mg/50 mL (100 mg/mL) SingleDose Vials and 10,000 mg/100 mL (100 mg/mL) Pharmacy Bulk Package. Glenmark’s Calcium Gluconate Injection USP is bioequivalent and therapeutically equivalent to the reference listed drug, Calcium Gluconate Injection, 1,000 mg/10 mL (100 mg/mL), 5,000 mg/50 mL (100 mg/mL) and 10,000 mg/100 mL (100 mg/mL), of Fresenius Kabi USA, LLC [NDA 208418].
The above information is a part of company’s filings submitted to BSE.
No Records Found
The current share price of Centenial Surgical Suture Ltd. is ₹97.50 as of 2026-08-21.
The market capitalisation of Centenial Surgical Suture Ltd. is ₹35.57 as of 2026-08-21.
The 1-year return of Centenial Surgical Suture Ltd. is -54.95% as of 2026-08-21.
The P/E ratio of Centenial Surgical Suture Ltd. is 0.00 as of 2026-08-22.
The 52-week high and low of Centenial Surgical Suture Ltd. are ₹189.00 and ₹73.04, respectively, as of 2026-08-21.
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.